Sign in
PPBT Stock Price, Chart, Stats & News
Purple Biotech Ltd.
Save
Purple Biotech Ltd. (PPBT) does not currently pay a dividend.
234,743
Market cap
–
Current P/E
–
Forward P/E
PPBT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -152.14% |
ROE | -99.81% |
D/E | 0.03x |
Interest coverage ratio | -27.40x |
PPBT valuation
P/E | – |
P/S | – |
P/B | 0.00x |
P/CF | -0.00x |
P/FCF | -0.16x |
P/OCF | -0.00x |
PEG | 0.00x |
EV multiple | -1.61x |
About
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer.
Similar securities
Based on sector and market capitalization
Report issue